Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

about

Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.

P2860

Q37818237-06ABAE2D-C436-4080-ABD8-0089CAF7A3C0 Q42907386-E03111AF-CBFC-425B-8032-2694C86BAEAF

P2860

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

Item

http://www.wikidata.org/entity/Q42933928

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Formulation preference, tolera ...... iency virus-infected patients.

@en

Formulation preference, tolera ...... iency virus-infected patients.

@nl

type

Item

label

Formulation preference, tolera ...... iency virus-infected patients.

@en

Formulation preference, tolera ...... iency virus-infected patients.

@nl

prefLabel

Formulation preference, tolera ...... iency virus-infected patients.

@en

Formulation preference, tolera ...... iency virus-infected patients.

@nl

P1476

Formulation preference, tolera ...... iency virus-infected patients.

@en

P2093

Brian Schmotzer

http://www.w3.org/2001/XMLSchema#string

Ighovwerha Ofotokun

http://www.w3.org/2001/XMLSchema#string

Kelly L O'Neil

http://www.w3.org/2001/XMLSchema#string

Susan K Chuck

http://www.w3.org/2001/XMLSchema#string

P2860

Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease

Management of protease inhibitor-associated diarrhea.

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.

Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

P2888

1742-6405-6-29

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-6405-6-29

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40759046

http://www.w3.org/2001/XMLSchema#string

P6179

1015229638

http://www.w3.org/2001/XMLSchema#string

P698

20028544

http://www.w3.org/2001/XMLSchema#string

P932

2809072

http://www.w3.org/2001/XMLSchema#string

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

about

P2860

P2860

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932